News

Santé log1h
EssilorLuxottica and Meta to launch Oakley Meta, creating a new category of Performance AI glasses for athletes and fans alike
EssilorLuxottica and Meta Platforms announced Oakley Meta, a new category of Performance AI glasses that pair Meta’s industry-leading AI technology with Oakley’s pioneering design and PRIZM lenses to ...
Santé log1h
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for QINLOCK® (ripretinib)
Ripretinib is a tyrosine kinase inhibitor that inhibits KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet derived growth factor receptor A (PDGFRA) kinase, including wild type, primary, ...
Santé log1h
SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors
Nirogacestat exhibited a manageable safety and tolerability profile. The most common adverse reactions reported in patients receiving nirogacestat were diarrhea, ovarian toxicity, rash, nausea, ...
Santé log1h
Safety Shot Provides Update on Expected Closing of Yerbaé Brands Corp. Acquisition
SCOTTSDALE, AZ, June 20, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or the “Company”) today provided an update on the expected timing for the closing of its previously ...
Santé log4h
Dr. Anosh Ahmed’s Philanthropic Vision: Empowering Underserved Chicago Communities
Dr. Anosh Ahmed is a Chicago-based physician, entrepreneur, and philanthropist known for his leadership in healthcare and ...
Santé log4h
Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
European Commission decision expected in August 2025; if approved, resmetirom will be the first medication for people living with MASH in the E.U. CONSHOHOCKEN, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- ...
Santé log4h
DARZALEX® (daratumumab) receives the first positive CHMP opinion for patients with high-risk smouldering multiple myeloma
If approved, daratumumab will be the first authorised treatment option for patients with smouldering multiple myeloma at high-risk of developing multiple myeloma, offering the potential for disease ...
Santé log4h
CHMP recommends third indication for darolutamide for patients with advanced prostate cancer
CHMP recommends third indication for darolutamide for patients with advanced prostate cancer CHMP adopts positive opinion for the marketing authorisation of darolutamide in combination with androgen ...
Santé log4h
Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors
The positive CHMP opinion is based on data from the CABINET Phase III trial, which investigated Cabometyx versus placebo in people living with advanced pNETs or epNETs, whose disease had progressed ...
Santé log7h
NEUROBLASTOME : Nouvelle stratégie de différenciation pour un cancer pédiatrique grave
Accèdez sans limite aux 15 000 actualités du site et recevez gratuitement chaque semaine, la Newsletter Santé log avec les ...
Santé log7h
NANOTHÉRAPIE : Sucrée, elle ensuque les amyloïdes toxiques
Accèdez sans limite aux 15 000 actualités du site et recevez gratuitement chaque semaine, la Newsletter Santé log avec les ...
Santé log7h
Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)
Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP) Approval based on pivotal results showing improvements in sustained disease ...